Open Access

Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: A meta‑analysis of 14 randomized controlled trials

  • Authors:
    • Shanlian Wu
    • Liang Yao
    • Peijing Yan
    • Qiangwei Bao
    • Xin Dong
    • Xingguang Liu
    • Yan Zhu
    • Xin Su
    • Aqian Wang
    • Yichao Duan
    • Kehu Yang
    • Min Zhang
    • Yunshan Cao
  • View Affiliations

  • Published online on: February 15, 2019     https://doi.org/10.3892/etm.2019.7283
  • Pages: 2985-2994
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Autologous bone marrow stem cell (BMSC) therapy is a novel option for regenerative therapy in patients with ischemic heart disease. The aim of the present meta‑analysis was to evaluate the effectiveness of BMSCs combined with coronary artery bypass grafting (CABG). The PubMed, Cochrane Library, EMBASE and Web of Science databases were searched from inception to November 22, 2017 for randomized controlled trials on BMSC therapy combined with CABG. Finally, 14 trials with a total of 596 participants were included. Data were analyzed using a random‑effects model. Compared with the control group, the BMSC therapy group exhibited an improvement in the left ventricular (LV) ejection fraction from baseline to follow‑up [mean difference (MD)=4.36%; 95% confidence interval (CI): 1.90‑6.81%; P<0.01]. Analysis of the pooled results revealed non‑significant differences in the LV end‑diastolic volume (MD=‑6.27 ml; 95% CI: ‑22.34 to 9.80 ml; P=0.44), LV end‑diastolic volume index (MD=‑15.11 ml/m2; 95% CI: ‑31.53 to 1.30 ml/m2; P=0.07), LV end‑systolic volume (MD=‑11.52 ml; 95% CI: ‑26.97 to 3.93 ml; P=0.14) and LV end‑systolic volume index (MD=‑16.56 ml/m2; 95% CI: ‑37.75 to 4.63 ml/m2; P=0.13) between the BMSC and CABG alone groups. Therefore, autologous BMSC therapy for patients undergoing CABG appears to be associated with an improvement in LV function compared with CABG alone.
View Figures
View References

Related Articles

Journal Cover

April-2019
Volume 17 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu S, Yao L, Yan P, Bao Q, Dong X, Liu X, Zhu Y, Su X, Wang A, Duan Y, Duan Y, et al: Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: A meta‑analysis of 14 randomized controlled trials. Exp Ther Med 17: 2985-2994, 2019
APA
Wu, S., Yao, L., Yan, P., Bao, Q., Dong, X., Liu, X. ... Cao, Y. (2019). Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: A meta‑analysis of 14 randomized controlled trials. Experimental and Therapeutic Medicine, 17, 2985-2994. https://doi.org/10.3892/etm.2019.7283
MLA
Wu, S., Yao, L., Yan, P., Bao, Q., Dong, X., Liu, X., Zhu, Y., Su, X., Wang, A., Duan, Y., Yang, K., Zhang, M., Cao, Y."Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: A meta‑analysis of 14 randomized controlled trials". Experimental and Therapeutic Medicine 17.4 (2019): 2985-2994.
Chicago
Wu, S., Yao, L., Yan, P., Bao, Q., Dong, X., Liu, X., Zhu, Y., Su, X., Wang, A., Duan, Y., Yang, K., Zhang, M., Cao, Y."Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: A meta‑analysis of 14 randomized controlled trials". Experimental and Therapeutic Medicine 17, no. 4 (2019): 2985-2994. https://doi.org/10.3892/etm.2019.7283